FROM THE TEAM
Cubic Health is on the Move
After four years at our King Street East address, we are pleased to announce that Cubic Health is moving into our new office space near the intersection of King Street West and Spadina Avenue in downtown Toronto on November 23, 2007. The new address will be as follows:
Cubic Health Inc.
11 Charlotte Street, Suite #301,
Toronto, ON
M5V 2H5
The existing telephone numbers will remain unchanged at (416) 203-1446 and toll free at 1-(877)-CUBIC-50.
We are excited to be expanding into this larger space to facilitate our work on a growing number of diverse engagements in the management of the prescription drug benefit for clients in the private and public sectors in Canada. We look forward to hosting our clients and vendors early in 2008 when we are settled into the new space.
To pass along any comments on Cubic Health Monthly, or to see back issues of our publication, please visit our website at http://www.cubichealth.ca.
Sincerely,
Chris von Heymann
Senior Vice President, Consulting Services
| DRUG & DISEASE NEWS |
Prexige® Market Withdrawal
Just shy of one year from when it received its Notice of Compliance (NOC) from Heath Canada, market authorization for Prexige® was withdrawn on October 4th, 2007. The removal of Prexige® (lumaricoxib), an anti-inflammatory in the COX-2 Inhibitor class, follows closely in the footsteps of Vioxx® and Bextra® which were withdrawn from the market in 2004 and 2005, respectively. Vioxx® was withdrawn because of increased risk of cardiovascular events, Bextra® for serious skin reactions, and now Prexige® for increased risk of liver toxicity.
Click here to read more...
|
NOC Watch:
Emend® (aprepitant)
Zeldox® (ziprasidone) and Invega™ (paliperidone)
Elaprase™ (idursulfase)
Avamys™ (fluticasone furoate)
Click here to read more...
|
| FOR THE PLAN SPONSOR |
Cubic Health Releases Updated Adherence With Therapy Analysis
Cubic Health is pleased to announce the availability of our newly updated Adherence with Therapy Analysis. It is widely accepted that in North America, as many as half of all patients receiving chronic drug therapy for conditions such as high blood pressure, high cholesterol, depression, and diabetes do not properly adhere to their prescribed treatment regimen. A lack of adherence to therapy can have significant negative implications for Canadian employers, especially in areas such as mental illness. It can lead to greater absenteeism, lower productivity, and eventually to short-term or long-term disability.
Click here to read more...
|
|
